Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Samsung Biologics Co.,Ltd. (207940.KS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.11 B | 4.46 B | 11.52 B | 3.96 B | |
| 2022 | 588.62 M | 1.16 B | 5.45 B | 11.9 B | 4.63 B |
| 2021 | 308.78 M | 893.76 M | 2.14 B | 5.72 B | 2.03 B |
| 2020 | 542.61 M | 1.31 B | 4.61 B | 1.26 B | |
| 2019 | 379.37 M | 1.12 B | 4.24 B | 973.37 M |